AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of MediPharm Labs.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
MediPharm Labs
Canada Flag
Country
Country
Canada
Address
Address
151 John St. Barrie, ON L4N 2L1
Telephone
Telephone
+1 7057197425

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.


Lead Product(s): Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: Pink Kush

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.


Lead Product(s): Cannabis-derived Therapy

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Avicanna

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.


Lead Product(s): Cannabidiol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.


Lead Product(s): Cannabis-derived Therapy

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.


Lead Product(s): Cannabidiol,Tetrahydrocannabinol

Therapeutic Area: Neurology Product Name: T2:C100

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $16.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 09, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.


Lead Product(s): Cannabigerol,Cannabidiol

Therapeutic Area: Neurology Product Name: CBG:CBD

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.


Lead Product(s): Cannabidiol,Cannabigerol

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 05, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.


Lead Product(s): Cannabidiol

Therapeutic Area: Sleep Product Name: CBD50

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: McMaster University

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 31, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.


Lead Product(s): Cannabidiol,Tetrahydrocannabinol

Therapeutic Area: Sleep Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: McMaster University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 21, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY